Phosphorus Announces Formation of Scientific Advisory Board
The new advisory board consists of leaders in translational, cardiovascular, and reproductive genetics.
New York. February 28, 2017.
Phosphorus, a computational genomics and clinical genetic testing company, announced today the formation of the Phosphorus Scientific Advisory Board, an established group of medical and science experts chosen to advise the company on the development of new products and the company’s large-scale, multi-site research initiatives. Please visit http://phosphorus.com/about-us/ to learn more about the Phosphorus team and initiatives.
“We’ve gathered some of the top leaders in the field of genetics together with clinical practitioners in a few key focus areas, including reproductive health and cardiology,” said Alexander Bisignano, co-founder and CEO of Phosphorus. “We’re eager to leverage their expertise as we continue on our mission to create a world where every healthcare decision is optimized with genomics.”
The Scientific Advisory Board members include:
- Harold Swerdlow, Ph.D. Vice President of Sequencing at New York Genome Center. Prior to joining NYGC, he served as Head of Research & Development at the Wellcome Trust Sanger Institute and was Senior Director of Research at Solexa Ltd. His work in technology innovation seeks to advance a variety of next-generation molecular biology techniques.
- Silvia G Priori, M.D., Ph.D. Professor of Cardiology at the University of Pavia in Italy. Dr. Priori is the Global Scientific Director, Director of Cardiology and Molecular Cardiology at the Istituti Clinici Scientifici Maugeri SpA & SB Pavia in Italy and Director of Cardiovascular Genetics at the Centro National de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain. Dr. Priori is a recognized pioneer in the field of inherited cardiovascular diseases.
- Samuel Dudley, MD, Ph.D. Chief of the Division of Cardiology at the Warren Alpert Medical School of Brown University and the Lifespan Health System. He has published more than 100 manuscripts and book chapters and is the inventor on more than 20 patents including a blood test to predict sudden death risk. He is Chief Science Officer of 3PrimeDx.
- Colleen Caleshu, ScM, CGC. Lead Genetic Counselor in the Stanford Center for Inherited Cardiovascular Disease and a Clinical Assistant Professor in Medical Genetics at Stanford University. Colleen is the past vicechair of the National Society of Genetic Counselors (NSGC) Education committee. She is also a past chair of the NSGC Cardiovascular Special Interest Group.
- David Hoffman, M.D. Reproductive Endocrinologist at IVF Florida Reproductive Associates. He has over 30 years of experience in the diagnosis and treatment of infertility and has published over 65 abstracts, articles, and book chapters. David Hoffman, M.D., also serves as a Clinical Associate Professor of OB/GYN at both Florida International University and Florida Atlantic University Schools of Medicine and a Voluntary Associate Professor at the University of Miami, School of Medicine.
- Serena H. Chen, M.D. Director for the Division of Reproductive Medicine in the Department of Obstetrics and Gynecology at Saint Barnabas Medical Center and the Institute for Reproductive Medicine and Science at Saint Barnabas. She is a highly regarded advocate of reproductive technology access and reproductive health awareness and has been at the forefront of advanced reproductive technologies.
- Jacques Cohen, Ph.D., HCLD. Director of The Art Institute of Washington and a co-founder of Reprogenetics, purchased by CooperSurgical. He was an embryologist at Bourn Hall Clinic, the world’s first IVF clinic directed by Robert G. Edwards (Nobel Prize in Medicine in 2010). He has authored more than 200 publications and has developed several techniques used in IVF laboratories worldwide.
- Shahin Gadhir, M.D. Founding partner of Southern California Reproductive Center and an Assistant Clinical Professor in the Department of Obstetrics and Gynecology at UCLA and USC. He has conducted and published considerable research on women’s health and fertility issues.
Phosphorus is a computational genomics and clinical genetic testing company with the vision to create a world where every healthcare decision is optimized with genomics. Based in New York City, Phosphorus develops powerful data-driven software that enables labs around the world to deliver the most advanced genetic tests. Phosphorus is committed to an active research and development program with an initial focus on decoding the genetic causes of infertility and inherited cardiovascular disease. With a team of experts in computational biology and computer science, Phosphorus is building a data network that will help providers, researchers and patients around the world better understand and harness the power of the human genome. For more information visit: www.phosphorus.com and @phosphorus.